Experience of treatment of lung cancer patients using paclitaxel and carboplatin

Anwar Jusuf, Sutji Astuti Mariono, Karmel Lindow Tambunan, A. Harryanto Reksodiputro, Noorwati Soetandyo, Ronald Hukom, Eddy Suratman, A. Mulawarman Jayusman

Research output: Contribution to journalArticlepeer-review


Nineteen patients with stage III & IV nonsmali cell lung cancer were treated with regimen containing pacUtaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina General Hospital, Jakarta-Indonesia. There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquanwus carcinoma in I patient. Fourteen patients were in stage IV, 4 had stage IIIB, one had stage IIIA disease. The regimen contains pacUtaxel 135-200 mg/m2, combined with carboplatin 300 mg/m2 orAUC 6 mg/ml. min, given every 3 weeks. Those who underwent at least 3 cycles of chemotherapy were followed up until death. Objective improvement (partial response) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%). Two patients are still alive at 22 months and 23 months after starting chemotherapy. The one year survival rate was 58% and median survival time was 14 months.

Original languageEnglish
Pages (from-to)43-48
Number of pages6
JournalMedical Journal of Indonesia
Issue number1
Publication statusPublished - 1 Jan 2000


  • Carboplatin
  • Chemotherapy
  • Nonsmall cell carcinoma
  • Paclitaxel


Dive into the research topics of 'Experience of treatment of lung cancer patients using paclitaxel and carboplatin'. Together they form a unique fingerprint.

Cite this